scholarly journals An abnormal bone marrow microenvironment contributes to hematopoietic dysfunction in Fanconi anemia

Haematologica ◽  
2017 ◽  
Vol 102 (6) ◽  
pp. 1017-1027 ◽  
Author(s):  
Yuan Zhou ◽  
Yongzheng He ◽  
Wen Xing ◽  
Peng Zhang ◽  
Hui Shi ◽  
...  
2010 ◽  
Vol 19 (2) ◽  
pp. 203-208 ◽  
Author(s):  
Séverine Lecourt ◽  
Valérie Vanneaux ◽  
Thierry Leblanc ◽  
Gwenaelle Leroux ◽  
Brigitte Ternaux ◽  
...  

Blood Science ◽  
2021 ◽  
Vol 3 (2) ◽  
pp. 29-34
Author(s):  
Zehui Chen ◽  
Yaxin Zheng ◽  
Yaling Yang ◽  
Junnan Kang ◽  
M. James You ◽  
...  

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 3629-3629
Author(s):  
Yan Li ◽  
Shi Chen ◽  
Yongzheng He ◽  
Xiaohong Li ◽  
Fengchun Yang

Abstract Abstract 3629 Poster Board III-565 Fanconi anemia (FA) is a heterogeneous genetic disorder characterized by progressive bone marrow failure (BMF) and acquisition of malignancies. The only cure for BMF is a human leukocyte antigen (HLA)-matched BM transplantation from a family member or autologous stem cells before BMF develops. Therefore, mobilization of hematopoietic stem/progenitor cells (HSPCs) from BM into peripheral blood (PB) for collection has been a prerequisite for the therapy. However, patients with FA show a markedly decreased HSPC mobilization in response to the traditional mobilizing drug G-CSF and the mechanism(s) underlying the defect remains unknown. Mesenchymal stem/progenitor cells (MSPCs) have been known to be the common progenitor of a variety of cellular components in the bone marrow microenvironment. MSPCs express/secrete cytokines, extracellular matrix proteins and cell adhesion molecules, which regulate the homing, migration, proliferation and survival of HSPCs in vitro and in vivo. Recently, we reported that Fancg-/- MSPCs have a defect in hematopoietic supportive activity both in vitro and in vivo (Li et al. Blood, 2009). In the current studies, we show that Fancg-/- MSPCs have significant reduction in HSPC recruitment as compared to WT MSPCs in a transwell assay. Furthermore, Fancg-/- MSPCs have an alteration in the production of multiple cytokines/chemokines. Application of a neutralizing antibody to the cytokine blocked WT MSPC mediated HSPC migration in vitro. Furthermore, administration of the specific cytokine significantly increased HSPC mobilization in the Fancg-/- mice in vivo. These results demonstrated that an impaired BM microenvironment, specifically MSPCs in Fancg-/- mice, is contributory to defective HSPC mobilization. This study provides evidence of alternative clinical therapeutics for the mobilization of HSPCs in FA patients. Disclosures: No relevant conflicts of interest to declare.


2016 ◽  
Author(s):  
Anjali Kusumbe ◽  
Saravana Ramasamy ◽  
Tomer Itkin ◽  
Tsvee Lapidot ◽  
Ralf Adams

Sign in / Sign up

Export Citation Format

Share Document